TY - JOUR T1 - Chemotherapy outcome of pulmonary tuberculosis with mutations in the FN1 and TNXB genes JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.4592 VL - 56 IS - suppl 64 SP - 4592 AU - Kirill Samsonov AU - Anna Mordyk Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/4592.abstract N2 - Introduction: Treatment of pulmonary tuberculosis (TB) under identical conditions is not always effective. We’ve found out the reason of this phenomenon in the structural and functioning features of the intercellular matrix that has important substances, fibronectin and tenascin-X.Aims: Study of the effect of the rN6707530 polymorphism of the FN1 gene and the rs1150754 polymorphism of the TNXB gene on the effectiveness of chemotherapy for pulmonary TB.Methods: The research included 184 patients with pulmonary TB, which divided into 2 groups with ineffective (n=93) and effective (n=91) chemotherapy were allocated.Results: The distribution of FN1 genotypes in patients with ineffective chemotherapy was as follows: T\T – 66,7%, T\G – 30,1%, G\G – 3,2%, in patients with effective treatment was different: T\T – 3,2% (p<0,001), T\G – 49,4% (p=0,008), G\G – 15,4% (p=0,01). The distribution of TNXB genotypes was C\C – 80,6% and 84,6% (p=0,5), C\T – 18,3% and 15,4% (p=0,6) in the groups, genotype T\T was detected in only 1 (1,1%) patient group with ineffective therapy. Carriers of the T\T genotype of the FN1 hade cavities more than 2cm in diameter in 68,3%, with the T\G - in 10,2% (pTT\TG <0,001), with the G\G - in 11,1% (pTT\G =0,004). Decay cavities were closed after 6 months of chemotherapy in 6,3% of T\T carriers of the FN1, 30% of T\G (pTT\TG=0,003) and 57,1% of G\G (pTT\GG=0,004).Conclusions: Carriers of the T\T genotype rs6707530 of the FN1 polymorphism are less responsive to chemotherapy, have larger decay cavities that heal more slowly than the T\G and G\G. Polymorphism rs1150754 of the TNXB didn’t influence on the effectiveness of chemotherapy pulmonary TB.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4592.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -